
ReproNovo has dosed the first participant in its phase 2 NORDIC study evaluating RPN-002, an investigational therapy designed to improve …

ReproNovo has appointed Mark Altmeyer as Chairman of the Board of Directors. Bringing over 35 years of experience to the …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

